Intrinsic value of CareDx - CDNA

Previous Close

$29.71

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$29.71

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of CDNA stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  48.00
  43.70
  39.83
  36.35
  33.21
  30.39
  27.85
  25.57
  23.51
  21.66
  19.99
  18.49
  17.14
  15.93
  14.84
  13.85
  12.97
  12.17
  11.45
  10.81
  10.23
  9.71
  9.23
  8.81
  8.43
  8.09
  7.78
  7.50
  7.25
  7.03
Revenue, $m
  72
  103
  144
  196
  261
  340
  435
  546
  675
  821
  985
  1,167
  1,367
  1,585
  1,821
  2,073
  2,342
  2,627
  2,927
  3,244
  3,576
  3,923
  4,285
  4,662
  5,055
  5,464
  5,889
  6,331
  6,790
  7,267
Variable operating expenses, $m
  136
  194
  270
  366
  486
  632
  807
  1,012
  1,249
  1,519
  1,817
  2,153
  2,522
  2,924
  3,358
  3,823
  4,319
  4,845
  5,400
  5,983
  6,595
  7,235
  7,904
  8,600
  9,325
  10,079
  10,863
  11,678
  12,525
  13,404
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  136
  194
  270
  366
  486
  632
  807
  1,012
  1,249
  1,519
  1,817
  2,153
  2,522
  2,924
  3,358
  3,823
  4,319
  4,845
  5,400
  5,983
  6,595
  7,235
  7,904
  8,600
  9,325
  10,079
  10,863
  11,678
  12,525
  13,404
Operating income, $m
  -65
  -91
  -126
  -170
  -225
  -292
  -372
  -466
  -574
  -698
  -832
  -986
  -1,155
  -1,339
  -1,538
  -1,751
  -1,978
  -2,218
  -2,472
  -2,740
  -3,020
  -3,313
  -3,619
  -3,938
  -4,270
  -4,615
  -4,974
  -5,347
  -5,735
  -6,138
EBITDA, $m
  -57
  -83
  -115
  -157
  -210
  -273
  -350
  -439
  -542
  -660
  -791
  -938
  -1,099
  -1,274
  -1,463
  -1,665
  -1,881
  -2,110
  -2,352
  -2,606
  -2,872
  -3,151
  -3,442
  -3,745
  -4,061
  -4,390
  -4,731
  -5,086
  -5,455
  -5,838
Interest expense (income), $m
  1
  7
  11
  21
  34
  51
  71
  97
  127
  162
  203
  249
  301
  358
  422
  491
  565
  645
  730
  821
  916
  1,016
  1,121
  1,231
  1,346
  1,465
  1,590
  1,719
  1,854
  1,994
  2,139
Earnings before tax, $m
  -72
  -103
  -147
  -204
  -276
  -363
  -469
  -593
  -736
  -900
  -1,081
  -1,287
  -1,513
  -1,761
  -2,028
  -2,316
  -2,623
  -2,949
  -3,293
  -3,656
  -4,036
  -4,434
  -4,850
  -5,284
  -5,735
  -6,205
  -6,693
  -7,201
  -7,729
  -8,277
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -72
  -103
  -147
  -204
  -276
  -363
  -469
  -593
  -736
  -900
  -1,081
  -1,287
  -1,513
  -1,761
  -2,028
  -2,316
  -2,623
  -2,949
  -3,293
  -3,656
  -4,036
  -4,434
  -4,850
  -5,284
  -5,735
  -6,205
  -6,693
  -7,201
  -7,729
  -8,277

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  125
  179
  250
  341
  455
  593
  758
  952
  1,176
  1,430
  1,716
  2,034
  2,382
  2,762
  3,172
  3,611
  4,079
  4,576
  5,100
  5,651
  6,229
  6,834
  7,465
  8,123
  8,807
  9,519
  10,260
  11,029
  11,829
  12,660
Adjusted assets (=assets-cash), $m
  125
  179
  250
  341
  455
  593
  758
  952
  1,176
  1,430
  1,716
  2,034
  2,382
  2,762
  3,172
  3,611
  4,079
  4,576
  5,100
  5,651
  6,229
  6,834
  7,465
  8,123
  8,807
  9,519
  10,260
  11,029
  11,829
  12,660
Revenue / Adjusted assets
  0.576
  0.575
  0.576
  0.575
  0.574
  0.573
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
  0.574
Average production assets, $m
  38
  55
  76
  104
  139
  181
  231
  291
  359
  437
  524
  621
  728
  843
  969
  1,103
  1,246
  1,397
  1,557
  1,726
  1,902
  2,087
  2,280
  2,480
  2,689
  2,907
  3,133
  3,368
  3,612
  3,866
Working capital, $m
  -40
  -58
  -80
  -110
  -146
  -191
  -244
  -306
  -378
  -460
  -552
  -654
  -766
  -888
  -1,020
  -1,161
  -1,311
  -1,471
  -1,639
  -1,817
  -2,002
  -2,197
  -2,399
  -2,611
  -2,831
  -3,060
  -3,298
  -3,545
  -3,802
  -4,069
Total debt, $m
  56
  106
  170
  252
  354
  478
  627
  801
  1,002
  1,232
  1,489
  1,775
  2,089
  2,430
  2,799
  3,194
  3,616
  4,063
  4,534
  5,030
  5,551
  6,095
  6,663
  7,255
  7,871
  8,512
  9,178
  9,871
  10,591
  11,339
Total liabilities, $m
  112
  161
  225
  307
  409
  534
  682
  857
  1,058
  1,287
  1,545
  1,830
  2,144
  2,486
  2,855
  3,250
  3,671
  4,118
  4,590
  5,086
  5,606
  6,150
  6,718
  7,310
  7,927
  8,568
  9,234
  9,927
  10,646
  11,394
Total equity, $m
  12
  18
  25
  34
  45
  59
  76
  95
  118
  143
  172
  203
  238
  276
  317
  361
  408
  458
  510
  565
  623
  683
  746
  812
  881
  952
  1,026
  1,103
  1,183
  1,266
Total liabilities and equity, $m
  124
  179
  250
  341
  454
  593
  758
  952
  1,176
  1,430
  1,717
  2,033
  2,382
  2,762
  3,172
  3,611
  4,079
  4,576
  5,100
  5,651
  6,229
  6,833
  7,464
  8,122
  8,808
  9,520
  10,260
  11,030
  11,829
  12,660
Debt-to-equity ratio
  4.530
  5.890
  6.780
  7.370
  7.780
  8.060
  8.270
  8.420
  8.530
  8.610
  8.680
  8.730
  8.770
  8.800
  8.820
  8.850
  8.860
  8.880
  8.890
  8.900
  8.910
  8.920
  8.930
  8.930
  8.940
  8.940
  8.950
  8.950
  8.950
  8.960
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -72
  -103
  -147
  -204
  -276
  -363
  -469
  -593
  -736
  -900
  -1,081
  -1,287
  -1,513
  -1,761
  -2,028
  -2,316
  -2,623
  -2,949
  -3,293
  -3,656
  -4,036
  -4,434
  -4,850
  -5,284
  -5,735
  -6,205
  -6,693
  -7,201
  -7,729
  -8,277
Depreciation, amort., depletion, $m
  7
  9
  10
  13
  15
  19
  22
  27
  32
  38
  41
  48
  56
  65
  75
  85
  97
  108
  121
  134
  147
  162
  177
  192
  208
  225
  243
  261
  280
  300
Funds from operations, $m
  -64
  -94
  -137
  -192
  -261
  -345
  -446
  -566
  -704
  -862
  -1,040
  -1,239
  -1,457
  -1,695
  -1,953
  -2,230
  -2,526
  -2,840
  -3,172
  -3,522
  -3,889
  -4,272
  -4,673
  -5,091
  -5,527
  -5,980
  -6,450
  -6,940
  -7,449
  -7,977
Change in working capital, $m
  -13
  -18
  -23
  -29
  -36
  -44
  -53
  -62
  -72
  -82
  -92
  -102
  -112
  -122
  -132
  -141
  -151
  -160
  -168
  -177
  -186
  -194
  -203
  -211
  -220
  -229
  -238
  -247
  -257
  -267
Cash from operations, $m
  -51
  -76
  -114
  -162
  -224
  -300
  -393
  -503
  -632
  -780
  -948
  -1,137
  -1,345
  -1,573
  -1,822
  -2,089
  -2,376
  -2,681
  -3,004
  -3,345
  -3,703
  -4,078
  -4,470
  -4,880
  -5,307
  -5,751
  -6,212
  -6,693
  -7,192
  -7,710
Maintenance CAPEX, $m
  -2
  -3
  -4
  -6
  -8
  -11
  -14
  -18
  -23
  -28
  -34
  -41
  -48
  -56
  -65
  -75
  -85
  -97
  -108
  -121
  -134
  -147
  -162
  -177
  -192
  -208
  -225
  -243
  -261
  -280
New CAPEX, $m
  -13
  -17
  -22
  -28
  -35
  -42
  -50
  -59
  -68
  -78
  -87
  -97
  -106
  -116
  -125
  -134
  -143
  -152
  -160
  -168
  -177
  -185
  -193
  -201
  -209
  -217
  -226
  -235
  -244
  -254
Cash from investing activities, $m
  -15
  -20
  -26
  -34
  -43
  -53
  -64
  -77
  -91
  -106
  -121
  -138
  -154
  -172
  -190
  -209
  -228
  -249
  -268
  -289
  -311
  -332
  -355
  -378
  -401
  -425
  -451
  -478
  -505
  -534
Free cash flow, $m
  -66
  -96
  -140
  -196
  -267
  -353
  -458
  -580
  -723
  -886
  -1,069
  -1,274
  -1,500
  -1,746
  -2,012
  -2,299
  -2,604
  -2,929
  -3,272
  -3,634
  -4,013
  -4,410
  -4,825
  -5,257
  -5,708
  -6,177
  -6,664
  -7,170
  -7,697
  -8,244
Issuance/(repayment) of debt, $m
  22
  49
  64
  82
  102
  124
  149
  174
  201
  229
  257
  286
  314
  342
  369
  395
  421
  447
  472
  496
  520
  544
  568
  592
  616
  641
  666
  693
  720
  748
Issuance/(repurchase) of shares, $m
  90
  108
  154
  213
  287
  377
  485
  612
  759
  926
  1,109
  1,318
  1,548
  1,799
  2,069
  2,360
  2,670
  2,998
  3,345
  3,711
  4,094
  4,495
  4,913
  5,349
  5,804
  6,276
  6,767
  7,278
  7,809
  8,360
Cash from financing (excl. dividends), $m  
  112
  157
  218
  295
  389
  501
  634
  786
  960
  1,155
  1,366
  1,604
  1,862
  2,141
  2,438
  2,755
  3,091
  3,445
  3,817
  4,207
  4,614
  5,039
  5,481
  5,941
  6,420
  6,917
  7,433
  7,971
  8,529
  9,108
Total cash flow (excl. dividends), $m
  47
  61
  79
  99
  122
  148
  176
  206
  237
  269
  297
  330
  363
  395
  426
  457
  487
  516
  545
  573
  601
  629
  656
  684
  712
  741
  770
  800
  831
  864
Retained Cash Flow (-), $m
  -90
  -108
  -154
  -213
  -287
  -377
  -485
  -612
  -759
  -926
  -1,109
  -1,318
  -1,548
  -1,799
  -2,069
  -2,360
  -2,670
  -2,998
  -3,345
  -3,711
  -4,094
  -4,495
  -4,913
  -5,349
  -5,804
  -6,276
  -6,767
  -7,278
  -7,809
  -8,360
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -43
  -47
  -76
  -114
  -165
  -229
  -309
  -406
  -521
  -657
  -812
  -988
  -1,186
  -1,404
  -1,643
  -1,903
  -2,183
  -2,482
  -2,801
  -3,138
  -3,493
  -3,866
  -4,257
  -4,665
  -5,092
  -5,536
  -5,997
  -6,478
  -6,977
  -7,496
Discount rate, %
  7.50
  7.88
  8.27
  8.68
  9.12
  9.57
  10.05
  10.55
  11.08
  11.63
  12.22
  12.83
  13.47
  14.14
  14.85
  15.59
  16.37
  17.19
  18.05
  18.95
  19.90
  20.89
  21.94
  23.04
  24.19
  25.40
  26.67
  28.00
  29.40
  30.87
PV of cash for distribution, $m
  -40
  -40
  -60
  -82
  -106
  -132
  -158
  -182
  -203
  -218
  -229
  -232
  -229
  -220
  -206
  -187
  -166
  -143
  -120
  -98
  -77
  -59
  -44
  -32
  -23
  -15
  -10
  -6
  -4
  -2
Current shareholders' claim on cash, %
  50.0
  5.2
  0.5
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

FINANCIAL RATIOS  of  CareDx (CDNA)

Valuation Ratios
P/E Ratio -16.2
Price to Sales 15.4
Price to Book 33.3
Price to Tangible Book
Price to Cash Flow -37.2
Price to Free Cash Flow -35.1
Growth Rates
Sales Growth Rate 46.4%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 1
Current Ratio 0
LT Debt to Equity 5.3%
Total Debt to Equity 126.3%
Interest Coverage -40
Management Effectiveness
Return On Assets -57.2%
Ret/ On Assets - 3 Yr. Avg. -26.5%
Return On Total Capital -88.6%
Ret/ On T. Cap. - 3 Yr. Avg. -37.9%
Return On Equity -162.5%
Return On Equity - 3 Yr. Avg. -64.9%
Asset Turnover 0.6
Profitability Ratios
Gross Margin 48.8%
Gross Margin - 3 Yr. Avg. 61.1%
EBITDA Margin -90.2%
EBITDA Margin - 3 Yr. Avg. -43.1%
Operating Margin -90.2%
Oper. Margin - 3 Yr. Avg. -43.1%
Pre-Tax Margin -100%
Pre-Tax Margin - 3 Yr. Avg. -51.2%
Net Profit Margin -95.1%
Net Profit Margin - 3 Yr. Avg. -47.1%
Effective Tax Rate 2.4%
Eff/ Tax Rate - 3 Yr. Avg. 67.5%
Payout Ratio 0%

CDNA stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the CDNA stock intrinsic value calculation we used $48.324 million for the last fiscal year's total revenue generated by CareDx. The default revenue input number comes from 0001 income statement of CareDx. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our CDNA stock valuation model: a) initial revenue growth rate of 48% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 7.5%, whose default value for CDNA is calculated based on our internal credit rating of CareDx, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of CareDx.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of CDNA stock the variable cost ratio is equal to 193.8%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for CDNA stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 20.2% for CareDx.

Corporate tax rate of 27% is the nominal tax rate for CareDx. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the CDNA stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for CDNA are equal to 53.2%.

Life of production assets of 12.9 years is the average useful life of capital assets used in CareDx operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for CDNA is equal to -56%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-6.134 million for CareDx - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 36.346 million for CareDx is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of CareDx at the current share price and the inputted number of shares is $1.1 billion.

RELATED COMPANIES Price Int.Val. Rating
TMO Thermo Fisher 237.69 199.97  hold
GHDX Genomic Health 78.89 51.74  hold
MYGN Myriad Genetic 31.00 33.87  sell
QGEN Qiagen 34.51 31.34  sell
GNMK GenMark Diagno 4.74 0.31  str.sell

COMPANY NEWS

▶ CareDx Announces Pricing of Public Offering of Common Stock   [Nov-13-18 11:19PM  GlobeNewswire]
▶ CareDx: 3Q Earnings Snapshot   [05:14PM  Associated Press]
▶ CareDx Reports Third Quarter Results   [04:01PM  GlobeNewswire]
▶ CareDx to Participate in Upcoming Investor Conferences   [Nov-07-18 08:00AM  GlobeNewswire]
▶ Harry Boxers four stocks to watch this week   [Nov-01-18 02:46PM  MarketWatch]
▶ CareDx Profiles AlloSeq Suite of NGS Products at ASHI   [Oct-02-18 08:00AM  GlobeNewswire]
▶ CareDx to Participate in Upcoming Investor Conference   [Sep-21-18 08:00AM  GlobeNewswire]
▶ CareDx Inc (NASDAQ:CDNA): Are Analysts Optimistic?   [Sep-18-18 11:10AM  Simply Wall St.]
▶ CareDx broadens HeartCare availability   [Sep-17-18 08:00AM  GlobeNewswire]
▶ Stock Market Forecast: More Gains, More Volatility   [Sep-07-18 03:57PM  Investor's Business Daily]
▶ CareDx to Participate in Upcoming Investor Conference   [Aug-15-18 09:00AM  GlobeNewswire]
▶ Here's Why CareDx Jumped 13.5% Today   [Aug-10-18 08:07PM  Motley Fool]
▶ CareDX stock soars nearly 20% after earnings   [Aug-09-18 07:40PM  MarketWatch]
▶ CareDx: 2Q Earnings Snapshot   [04:58PM  Associated Press]
▶ CareDx Reports Second Quarter Results   [04:01PM  GlobeNewswire]
▶ Flatiron Health CMO/CSO Joins CareDx Board of Directors   [Jun-28-18 08:00AM  GlobeNewswire]
▶ Here's Why CareDx Dropped Today   [Jun-22-18 02:55PM  Motley Fool]
▶ Best Growth Stocks To Buy Now   [May-15-18 12:02PM  Simply Wall St.]
▶ CareDx: 1Q Earnings Snapshot   [May-10-18 05:31PM  Associated Press]
▶ CareDx Reports First Quarter Results   [04:01PM  GlobeNewswire]
▶ CareDx expands NGS Transplant Product Offerings   [May-09-18 08:00AM  GlobeNewswire]
▶ CareDx Activities at American Transplant Congress   [May-01-18 08:00AM  GlobeNewswire]
▶ CareDx Closes Debt Refinancing   [Apr-18-18 08:00AM  GlobeNewswire]
▶ Olerup QTYPE® Receives CE Mark Certification   [Apr-13-18 08:00AM  GlobeNewswire]
▶ CareDx Launches HeartCare® for Heart Transplant Recipients   [Apr-10-18 08:00AM  GlobeNewswire]
▶ CareDx Announces Completion of Debt Conversion   [Mar-29-18 08:00AM  GlobeNewswire]
▶ CareDx reports 4Q loss   [Mar-22-18 04:42PM  Associated Press]
▶ CareDx, Inc. to Host Earnings Call   [12:00PM  ACCESSWIRE]
▶ CareDx to Refinance Debt with Perceptive Advisors   [Mar-01-18 07:30AM  GlobeNewswire]
▶ CareDx to Participate in Upcoming Investor Conferences   [Feb-07-18 08:00AM  GlobeNewswire]
▶ CareDx Leadership in cfDNA Highlighted at CEoT   [Feb-05-18 09:00AM  GlobeNewswire]
▶ First Patient Enrolled in AlloSure Registry   [Feb-01-18 08:00AM  GlobeNewswire]
▶ TRIO Honors Peter Maag with Transplant Innovation Award   [Jan-16-18 09:00AM  GlobeNewswire]
▶ 4 Top-Ranked Growth Stocks in MedTech Under $20   [Nov-30-17 02:54PM  Zacks]
▶ ETFs with exposure to CareDx, Inc. : November 27, 2017   [Nov-27-17 12:38PM  Capital Cube]
▶ CMS Releases 2018 Clinical Laboratory Fee Schedule   [Nov-20-17 08:00AM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : November 17, 2017   [Nov-17-17 11:33AM  Capital Cube]
▶ CareDx Further Simplifies its Balance Sheet   [Nov-15-17 09:00AM  GlobeNewswire]
▶ CareDx reports 3Q loss   [Nov-09-17 04:16PM  Associated Press]
▶ CareDx, Inc. to Host Earnings Call   [12:30PM  ACCESSWIRE]
▶ ETFs with exposure to CareDx, Inc. : November 7, 2017   [Nov-07-17 09:54AM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Nov-02-17 09:00AM  GlobeNewswire]
▶ AlloSure data will be presented at ASN   [Oct-30-17 08:00AM  GlobeNewswire]
▶ CareDx Announces Closing of Public Offering of Common Stock   [Oct-10-17 04:00PM  GlobeNewswire]
▶ How Does CareDx Inc (CDNA) Affect Your Portfolio Returns?   [Oct-05-17 07:45PM  Simply Wall St.]
▶ MolDX sets AlloSure reimbursement at 2017 AlloMap level   [Sep-26-17 08:30AM  GlobeNewswire]
▶ ETFs with exposure to CareDx, Inc. : September 25, 2017   [Sep-25-17 10:35AM  Capital Cube]
▶ AlloMaps Medicare reimbursement to increase in 2018   [Sep-22-17 05:26PM  GlobeNewswire]
▶ Have Investors Already Priced In CareDx Incs (CDNA) Growth?   [Sep-21-17 06:51PM  Simply Wall St.]
▶ This Market Knows No Fear   [01:41PM  TheStreet.com]
▶ ETFs with exposure to CareDx, Inc. : September 14, 2017   [Sep-14-17 06:04PM  Capital Cube]
▶ CareDx to Participate in Upcoming Investor Conferences   [Aug-15-17 08:00AM  GlobeNewswire]
▶ CareDx reports 2Q loss   [Aug-10-17 09:43PM  Associated Press]
▶ CareDx reports 2Q loss   [04:43PM  Associated Press]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.